---
figid: PMC3142564__nihms212276f3a
figlink: /pmc/articles/PMC149053/figure/fig7/
number: F3a
caption: Figure 3a. Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer.
  Inhibitors targeting major nodes of the PI3K signaling pathway, including RTKs,
  PI3K, AKT and mTOR, have reached clinical trials. Dual inhibitors targeting both
  PI3K and RTK or PI3K and mTOR (as shown in connected solid and dashed lines) may
  provide more potent therapeutic effects in suppressing the PI3K signaling. Combinations
  of PI3K and Raf/MAPK inhibitors may achieve more effective clinical results. mTOR,
  mammalian target of rapamycin; RTK, receptor tyrosine kinase; EGFR, epidermal growth
  factor receptor; Erbb2, Epidermal growth factor Receptor 2; c-Met, mesenchymal-epithelial
  transition factor Ras, a small GTPase protein, Raf, a serine/threonine kinase; MEK,
  mitogen-activated protein kinase kinase; ERK, extracellular signal regulated kinase.Figure
  3b. Inhibitors in clinical development that target the PI3K or related pathways.
  EGFR, epidermal growth factor receptor; Erbb2, Human Epidermal growth factor Receptor
  2; VEGFR, vascular endothelial growth factor receptor; RTK, receptor tyrosine kinase;
  mTOR, mammalian target of rapamycin. *Bevacizumab targets VEGF-A instead of VEGFR
  directly. **Both AZD8055 and OSI027 are ATP-competitive mTOR inhibitors that targets
  both mTORC1 and mTORC2.
pmcid: PMC3142564
papertitle: Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer.
reftext: Pixu Liu, et al. Nat Rev Drug Discov. ;8(8):627-644.
pmc_ranked_result_index: '29614'
pathway_score: 0.962016
filename: nihms212276f3a.jpg
figtitle: Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
year: ''
organisms: Homo sapiens
ndex: 018c6b5d-dec3-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3142564__nihms212276f3a.html
  '@type': Dataset
  description: Figure 3a. Targeting the phosphoinositide 3-kinase (PI3K) pathway in
    cancer. Inhibitors targeting major nodes of the PI3K signaling pathway, including
    RTKs, PI3K, AKT and mTOR, have reached clinical trials. Dual inhibitors targeting
    both PI3K and RTK or PI3K and mTOR (as shown in connected solid and dashed lines)
    may provide more potent therapeutic effects in suppressing the PI3K signaling.
    Combinations of PI3K and Raf/MAPK inhibitors may achieve more effective clinical
    results. mTOR, mammalian target of rapamycin; RTK, receptor tyrosine kinase; EGFR,
    epidermal growth factor receptor; Erbb2, Epidermal growth factor Receptor 2; c-Met,
    mesenchymal-epithelial transition factor Ras, a small GTPase protein, Raf, a serine/threonine
    kinase; MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal
    regulated kinase.Figure 3b. Inhibitors in clinical development that target the
    PI3K or related pathways. EGFR, epidermal growth factor receptor; Erbb2, Human
    Epidermal growth factor Receptor 2; VEGFR, vascular endothelial growth factor
    receptor; RTK, receptor tyrosine kinase; mTOR, mammalian target of rapamycin.
    *Bevacizumab targets VEGF-A instead of VEGFR directly. **Both AZD8055 and OSI027
    are ATP-competitive mTOR inhibitors that targets both mTORC1 and mTORC2.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - PIK3R5
  - HRAS
  - AKT2
  - NRAS
  - PIK3CB
  - PIK3R4
  - PIK3R6
  - MAPK1
  - MAPK3
  - KRAS
  - PIK3CA
  - BRAF
  - EGFR
  - MTOR
  - MAP2K1
  - PIK3CG
  - SLTM
  - AKT1
  - ARAF
  - MAP2K2
  - RAF1
  - ERBB2
  - PIK3R3
  - PIK3CD
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: C-Met
  symbol: Met
  source: hgnc_alias_symbol
  hgnc_symbol: SLTM
  entrez: '79811'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Erbb2
  symbol: ERBB2
  source: hgnc_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3142564__F3a
redirect_from: /figures/PMC3142564__F3a
figtype: Figure
---
